Clean Science reports record consolidated sales driven by the HALS segment scaling up, though legacy business faced raw material supply disruptions. Management is aggressively pivoting toward high-margin, advanced HALS chemistry via a new Swiss strategic collaboration.
Clean Science reported its highest-ever consolidated sales for Q1 FY27, reaching INR 268 Cr, driven by the HALS series expansion despite global headwinds.
Clean Science shows sequential recovery in Q4 FY26 despite global pricing pressures, with management voluntarily forgoing bonuses to support financials amidst a 19% YoY standalone revenue decline.
Clean Science reports FY26 consolidated revenue of ₹957 cr and PAT of ₹230 cr. EBITDA margins remain resilient at 37.7% despite challenging market conditions, underpinned by new HALS product launches.